-
公开(公告)号:US11110160B2
公开(公告)日:2021-09-07
申请号:US16774309
申请日:2020-01-28
Applicant: PFIZER INC.
Inventor: Jianxin Gu , Jin-hwan Kim , Avvari Krishna Prasad , Yu-ying Yang
IPC: A61K39/095 , A61K47/64 , A61K39/09 , A61K45/06 , A61K39/00
Abstract: The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.
-
42.
公开(公告)号:US20210196810A1
公开(公告)日:2021-07-01
申请号:US17194224
申请日:2021-03-06
Applicant: Pfizer Inc.
Inventor: Emilio Anthony Emini , Wendy Jo Watson , Avvari Krishna Prasad , Mingming Han , Jin-Hwan Kim , Jianxin Gu , Yu-ying Yang , Rajesh Kumar Kainthan , David Cooper , Michael William Pride , Kathrin Ute Jansen
Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
-
公开(公告)号:US10946086B2
公开(公告)日:2021-03-16
申请号:US16245378
申请日:2019-01-11
Applicant: Pfizer Inc.
Inventor: Annaliesa Sybil Anderson , Amardeep Singh Bhupender Bhalla , Robert G. K. Donald , Jianxin Gu , Kathrin Ute Jansen , Rajesh Kumar Kainthan , Lakshmi Khandke , Jin-Hwan Kim , Paul Liberator , Avvari Krishna Prasad , Mark Edward Ruppen , Ingrid Lea Scully , Suddham Singh , Cindy Xudong Yang
Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
公开(公告)号:US20210023200A1
公开(公告)日:2021-01-28
申请号:US17060944
申请日:2020-10-01
Applicant: Pfizer Inc.
Inventor: Ye Che , Philip Ralph Dormitzer , Alexey Vyacheslavovich Gribenko , Luke David Handke , Avvari Krishna Prasad , Xiayang Qiu , Mark Edward Ruppen , Xi Song , Kena Anne Swanson , Srinivas Kodali , Xin Xu , KariAnn Sweeney Efferen , Ping Cai , Kristin Rachael Tompkins , Lorna del Pilar Nunez
IPC: A61K39/155 , A61K39/12 , C07K14/005 , C12N7/00
Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
-
45.
公开(公告)号:US20200306357A1
公开(公告)日:2020-10-01
申请号:US16899738
申请日:2020-06-12
Applicant: Pfizer Inc.
Inventor: Emilio Anthony Emini , Wendy Jo Watson , Avvari Krishna Prasad , Mingming Han , Jin-Hwan Kim , Jianxin Gu , Yu-ying Yang , Rajesh Kumar Kainthan , David Cooper , Michael William Pride , Kathrin Ute Jansen
Abstract: The present invention relates to new immunogenic compositions comprising conjughated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
-
公开(公告)号:US20200246475A1
公开(公告)日:2020-08-06
申请号:US16852697
申请日:2020-04-20
Applicant: Pfizer Inc.
Inventor: Jianxin Gu , Rajesh Kumar Kainthan , Jin-Hwan Kim , Avvari Krishna Prasad , Yu-Ying Yang
Abstract: The present invention relates generally to glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a spacer containing ((2-oxoethyl)thio)). In an aspect the invention provides oxo-eT linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a ((2-oxoethyl)thio) spacer having the formula (I): wherein: A is a group (C═X)m wherein X is S or O and m is 0 or 1; B is a bond, O, or CH2; and when m is 0, B can also be (C═O); R is a C2-C16 alkylene, C2-C16 heteroakylene, NH—C(═O)—C2-C16 alkylene, or NH—C(═O)—C2-C16 heteroakylene, wherein said alkylene and heteroalkylene are optionally substituted by 1, 2 or 3 groups independently selected from COOR′ where R′ is selected from H, methyl, ethyl or propyl. The invention further relates to immunogenic compositions comprising such glycoconjugates, and to methods for the preparation and use of such glycoconjugates and immunogenic compositions.
-
公开(公告)号:US20190142922A1
公开(公告)日:2019-05-16
申请号:US16245378
申请日:2019-01-11
Applicant: Pfizer Inc.
Inventor: Annaliesa Sybil Anderson , Amardeep Singh Bhupender Bhalla , Robert G.K. Donald , Jianxin Gu , Kathrin Ute Jansen , Rajesh Kumar Kainthan , Lakshmi Khandke , Jin-Hwan Kim , Paul Liberator , Avvari Krishna Prasad , Mark Edward Ruppen , Ingrid Lea Scully , Suddham Singh , Cindy Xudong Yang
Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
公开(公告)号:US10238732B2
公开(公告)日:2019-03-26
申请号:US15896871
申请日:2018-02-14
Applicant: Pfizer Inc.
Inventor: Ye Che , Philip Ralph Dormitzer , Alexey Vyacheslavovich Gribenko , Luke David Handke , Avvari Krishna Prasad , Xiayang Qiu , Mark Edward Ruppen , Xi Song , Kena Anne Swanson , Srinivas Kodali , Xin Xu , KariAnn Sweeney Efferen , Ping Cai , Kristin Rachael Tompkins , Lorna del Pilar Nunez
IPC: A61K39/155 , C07K14/135 , C12N15/01 , C07K14/005 , C12N7/00 , A61K39/12 , A61K39/00
Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
-
公开(公告)号:US20180177864A1
公开(公告)日:2018-06-28
申请号:US15896871
申请日:2018-02-14
Applicant: Pfizer Inc.
Inventor: Ye Che , Philip Ralph Dormitzer , Alexey Vyacheslavovich Gribenko , Luke David Handke , Avvari Krishna Prasad , Xiayang Qiu , Mark Edward Ruppen , Xi Song , Kena Anne Swanson , Srinivas Kodali , Xin Xu , KariAnn Sweeney Efferen , Ping Cai , Kristin Rachael Tompkins , Lorna del Pilar Nunez
IPC: A61K39/155 , A61K39/12
CPC classification number: A61K39/155 , A61K39/12 , A61K2039/575 , C07K14/005 , C07K2319/02 , C07K2319/21 , C07K2319/22 , C07K2319/40 , C07K2319/70 , C07K2319/735 , C12N7/00 , C12N2760/18522 , C12N2760/18534 , C12N2760/18571
Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
-
公开(公告)号:US09950054B2
公开(公告)日:2018-04-24
申请号:US15347034
申请日:2016-11-09
Applicant: PFIZER INC.
Inventor: Jianxin Gu , Jin-hwan Kim , Avvari Krishna Prasad , Yu-ying Yang
IPC: A61K45/06 , A61K39/095 , A61K39/09 , A61K47/48 , A61K39/00
CPC classification number: A61K39/095 , A61K39/092 , A61K45/06 , A61K47/64 , A61K47/6415 , A61K47/646 , A61K2039/6037 , A61K2039/6068 , A61K2039/627
Abstract: The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.
-
-
-
-
-
-
-
-
-